On Jan. 06, Armistice Capital, LLC invested U.S. $8,000,003 in shares of EyeGate Pharmaceuticals Inc.. The Dir, 10% acquired 1,531,101 shares at a cost per share of $5.22. The transaction increased this specific insider’s holdings to 6,693,202 shares worth around $35.14 million at present.
H.C. Wainwright maintained its EyeGate Pharmaceuticals Inc. [EYEG] rating to the equivalent of a Buy but changed the price target to $14 from $10, in a research note dated December 22, 2020. That figure represents around a 62.5% premium from where the company’s shares closed on Friday. Other analysts also revised their coverage, with H.C. Wainwright’s analysts reiterating the shares to “a Buy” rating in a research note to investors issued in late December. Meanwhile, H.C. Wainwright had maintained its rating on EYEG to the earlier “Buy” rating, in a research note produced for clients November 12, 2020. In addition, there was no change from H.C. Wainwright on February 06, 2018. The rater maintained EYEG to “a Buy” but assigned new target price of $3.
Is EyeGate Pharmaceuticals Inc. [NASDAQ:EYEG] a Good Buy Right Now?
It should be noted that EYEG technical indicators for short, intermediate as well as long term progress have placed an overall average of 56% as Buy. The average signal changed from 24% Buy in the last week and compares with 56% Sell in the past month. Data from EyeGate Pharmaceuticals Inc.’s Trend Spotter indicated that the signals were Strengthening. The stock current average is 2.39 million shares in the past 20 days and the short term average signal indicates a 100% Buy. In the last 50 days, the average trading volume was 0.97 million shares while the medium term average advocated for Hold. The average long-term signal stands at 50% Buy and the 100-day average volume stands at 0.5 million shares.
EYEG Price Performance
On Wall Street, EyeGate Pharmaceuticals Inc. [NASDAQ:EYEG] finished Friday’s session up 1.55% at $5.25. The stock went up to $5.2776 at the same session while its lowest single day price was $5.10. In the last five days, it saw a rise of about 6.49%, EyeGate Pharmaceuticals Inc. shares gained by almost 6.49% since the beginning of the year. However, the share price has dropped to as low as -42.43% below its one year high. On 01/06/21, the company shares recorded $5.68, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 01/04/21, the same year at $4.79. The company’s shares have declined by -38.31% in the past year. The 50-day SMA achieved is $3.96 while the 200-day SMA is $4.49. Volume dropped to 45024.0 from 89500.0 in the previous session.
EYEG Stock Support And Resistance Levels
On the 24-hour scale, the immediate backing is perceived around 5.14 level, and in case of violation of this particular level, it will cause more drop to 5.03 level. On the upper level, 5.39 is still the key resistance. The stock may increase to the subsequent resistance at 5.32. The Relative Strength Index (RSI) pinned on the 14-day chart is 62.76, implying a neutral technical stance while the MACD stands at 0.12, meaning price will decrease in the next trading period. Percent R indicator moved to 63.42%, implying low price movement. Stochastic %K at 36.65% suggest holding the stock.
What is the short interest in EyeGate Pharmaceuticals Inc.?
Short interest in the EyeGate Pharmaceuticals Inc. stock has surged, increasing by 4350.0 shares to total 4970.0 shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 9320.0, data from Yahoo Finance shows. The decrease of -87.53% suggests the stock saw some decreased bullish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 0.19% of the overall float for the stock.
EyeGate Pharmaceuticals Inc.’s Biggest Shareholders: Who Owns EyeGate Pharmaceuticals Inc. [EYEG]?
Filings by Armistice Capital LLC showed that the firm now holds a total of 1,815,500 shares or roughly 39.24% of the outstanding EYEG shares. This means their shares have reduced by 0 from the 1,815,500 the investor reportedly held in its prior 13-F filing. With the conclusion of the sale, Geode Capital Management LLC updated stake is worth $115,949. Details in the latest 13F filings reveal that BlackRock Fund Advisors disposed off their 0.00% stake valued at $86,838 while The Vanguard Group, Inc. cut theirs at $38,638. During the last quarter, BlackRock Fund Advisors liquidated 0 of its shares in EyeGate Pharmaceuticals Inc. The US Bancorp Asset Management, Inc.’s holdings currently number 2,710 shares at $14227.5. According to the firm’s last 13F report, Golden State Wealth Management LL shares in the company at filing stood at 1,786 shares, roughly $5,912.
EYEG Earnings Forecast For The Current Quarter
EyeGate Pharmaceuticals Inc. [EYEG] is expected to report strong earnings results for the quarter ending on Dec 2020. The estimates represent 9,133.30% and 18.90% in the company’s revenue and earnings per share, respectively, on a year-on-year basis.
EYEG Earnings Estimates For The Current Year
For the financial year, EyeGate Pharmaceuticals Inc. [NASDAQ:EYEG] is expected to bring in revenue of $30k. The returns are nearly $-2.66 million lower than the company’s actual revenue recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it at -1.96, higher than that of FY19 by $0.27. Estimates put this year’s earnings growth at 12.10%, 18.90% for the next. As for sales, forecasts are for a decrease of -98.90% in the current fiscal year and a further 9,133.30% over the following year.
What are analyst thoughts on EyeGate Pharmaceuticals Inc.?
Looking forward to the EyeGate Pharmaceuticals Inc. share price prediction, we can see that analysts, surveyed by FactSet, offer the mean price target for EyeGate Pharmaceuticals Inc. stock at $15.00 within the next 12 months, which represents almost 65.0 per cent growth from its previous closing price of $5.25. The highest analysts’ target for EyeGate Pharmaceuticals Inc. stock projections is $15.50 and the lowest one is $14.00. Still, 2 analysts sharing their consensus rating for EYEG stock in 2021 agree that it is a Buy.